The purpose of this study is to compare the efficacy of Nivolumab and Relatlimab in combination with chemotherapy to Pembrolizumab with Chemotherapy in participants with stage IV or recurrent Non-squamous Non-small Cell Lung Cancer with PD-L1 expression ≥ 1%
The purpose of this study is to compare the efficacy of Nivolumab and Relatlimab in combination with chemotherapy to Pembrolizumab with Chemotherapy in participants with stage IV or recurrent Non-squamous Non-small Cell Lung Cancer with PD-L1 expression ≥ 1%
A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%
-
Local Institution - 0368, Tucson, Arizona, United States, 85723
Local Institution - 0111, Los Angeles, California, United States, 90404
Local Institution - 0112, Los Angeles, California, United States, 90404
Local Institution - 0304, Sacramento, California, United States, 95817
Local Institution - 0159, San Francisco, California, United States, 94115
Local Institution - 0206, Miami, Florida, United States, 33136
Local Institution - 0162, Pembroke Pines, Florida, United States, 33028
Local Institution - 0358, Saint Petersburg, Florida, United States, 33705
Local Institution - 0360, West Palm Beach, Florida, United States, 33401
Saint Elizabeth Medical Center Edgewood, Edgewood, Kentucky, United States, 41017
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
For general information about clinical research, read Learn About Studies.
18 Years to
ALL
No
Bristol-Myers Squibb,
Bristol-Myers Squibb, STUDY_DIRECTOR, Bristol-Myers Squibb
2033-11-11